Anjarium Biosciences

About:

Anjarium is focused on creating new class of non-viral gene therapies to deliver predictable ,inclusionary ways to tackle genetic diseases.

Website: http://www.anjarium.com/

Twitter/X: AnjariumBio

Top Investors: Surveyor Capital, Abingworth, Pfizer Venture Investments, Omega Funds, Gimv

Description:

Anjarium is focused on creating a new class of non-viral gene therapies to deliver more predictable, enduring, and inclusionary ways to tackle genetic diseases throughout a patient's lifetime. Combining deep domain expertise in synthetic and natural delivery systems, Anjarium is developing a novel class of bioinspired nanomedicine to address a range of genetic diseases, including those that necessitate very large gene delivery. Anjarium’s versatile platform systematically addresses key deficiencies of viral gene therapies in order to provide benefits to patients that have previously been out of reach.

Total Funding Amount:

55.5M CHF

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Schlieren, Zurich, Switzerland

Founded Date:

2017-01-01

Contact Email:

info(AT)anjarium.com

Founders:

Joel de Beer

Number of Employees:

1-10

Last Funding Date:

2021-09-15

IPO Status:

Private

Industries:

© 2025 bioDAO.ai